Experience

US WorldMeds

• United States
• Pharmaceutical Manufacturing
• 1 - 100 Employee

• Managing Director, Recovery Care & Allergy Division at US WorldMeds

  • May 2021 - 2 years 8 months

  Louisville, Kentucky, United States Current product portfolio includes LUCEMYRA (lofexidine), ZIMHI (naloxone), and SYMJEPI (epinephrine), with additional development work underway to grow the business.

• Senior Director, Business Development and Corporate Finance

  • Jul 2018 - 5 years 6 months

  Louisville, Kentucky Area Led $380 million divestiture of CNS division to Supernus, as well as the sale of ZELNORM (tegaserod) to Alfasigma. Completed four in-licensing transactions including for ZIMHI (naloxone) and SYMJEPI (epinephrine). Negotiated global partnering transactions for difluoromethylornithine (DFMO), including with Norgine for the EU rights.



KSL CAPITAL PARTNERS INTERNATIONAL, LLP

• United Kingdom
• Venture Capital and Private Equity Principals
• 1 - 100 Employee

• Vice President

  • Aug 2013 - Apr 2018

  Denver, CO Completed $1.7B of M&A transactions. Travel & leisure focused private equity fund.



Merrill Lynch

• United States
• Financial Services
• 700 & Above Employee

• Investment Banking Analyst, Real Estate

  • Jul 2011 - Jun 2013

  New York, NY Completed approximately $7 billion of M&A transactions and $6 billion of capital markets transactions



Vanderbilt University

• United States
• Higher Education
• 700 & Above Employee

• Teaching Assistant

  • Aug 2010 - May 2011

  Teaching Assistant for FNEC 261: Investment Analysis



Merrill Lynch

• United States
• Financial Services
• 700 & Above Employee

• Investment Banking Summer Analyst

  • Jun 2010 - Aug 2010



The Meridien Group

• Investment Banking Summer Analyst

  • May 2009 - Aug 2009



US WorldMeds, LLC

• Intern

  • Jun 2006 - Aug 2008

  Conducted hospital telesales and assisted in the initial marketing efforts of an injectable drug Researched new development opportunities which led to an ongoing engagement Reviewed a $3.2 million private placement memorandum and prepared applications for grants which resulted in $1.7 million in state incentives